Hoth Therapeutics Files 8-K

TL;DR

HOTH filed an 8-K on Nov 20, 2024, updating corporate info.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on November 20, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Nevada and its principal executive offices located at 590 Madison Avenue, New York, NY.

Why It Matters

This filing provides an update on Hoth Therapeutics' corporate and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• November 20, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 590 Madison Ave., 21st Floor New York, New York 10022 (address) — Principal Executive Offices
• (646) 756-2997 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001213900-24-100368.txt : 20241120 0001213900-24-100368.hdr.sgml : 20241120 20241120083036 ACCESSION NUMBER: 0001213900-24-100368 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241120 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241120 DATE AS OF CHANGE: 20241120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241478349 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0221896-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2024-11-20 2024-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  November 20, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave .,  21 st Floor New York ,  New York   10022 (Address of principal executive offices, including ZIP code)   ( 646 )  756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The  Nasdaq  Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐             Item 8.01 Other Events.   On November 20, 2024, Hoth Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company’s board of directors approved the Company’s purchase of up to $1 million in Bitcoin as a treasury reserve asset. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.   Risk Factors   The Company is supplementing the risk factors pre